Candidiasis Drugs Market Segmentation by Disease Type (Oral, Vaginal, Cutaneous, Invasive, and Others); by Drug Type {Butoconazole, Clotrimazole, Miconazole (Monistat, Vagistat, and Others), Nystatin, Tioconazole, and Others}; and by End-User (Hospitals, Retail Pharmacies, and Others) – Global Demand Analysis & Opportunity Outlook 2030

Buy Now Report ID: 3650 | Published Date: Feb 07, 2023

Global Candidiasis Drugs Market Regional Synopsis

On the basis of geographical analysis, the global candidiasis drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of increasing prevalence of candidiasis, backed by the climatic conditions that promote yeast infection. Moreover, lack of proper sanitation in the region, and lower rate of health awareness, especially in rural parts of the developing countries, is estimated to boost the regional market growth. The market in the Middle East and Africa region is also estimated to witness significant growth owing to the lack of hygiene and sanitation, and hot & humid climate of the region. 

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the constantly rising cases of candidiasis, especially invasive candidiasis in the region. As per a report by the CDC, approximately 25,000 cases of candidemia are recorded in the United States each year. The high prevalence of diabetes is one of the primary factors for the increasing candidiasis cases in the region.

Candidiasis Drugs Market

Get more information on this reportDownload Sample PDF

The global candidiasis drugs market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

Candidiasis Drugs Market
Get more information on this report: Request Free Sample PDF

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Market Segmentation


Our in-depth analysis of the global candidiasis drug market includes the following segments:

By Disease Type

  • Oral

  • Vaginal
  • Cutaneous
  • Invasive
  • Others

By Drug Type

  • Butoconazole
  • Clotrimazole
  • Miconazole
    • Monistat
    • Vagistat
    • Others
  • Nystatin
  • Tioconazole
  • Others

By End-User

  • Hospital
  • Retail Pharmacies
  • Others

Growth Drivers

  • Increasing Prevalence of Candidiasis
  • Rising R&D Activities for Drug Development
  • Easy Availability of Anti-fungal Drugs


  • Lack of Health Awareness amongst People
  • Absence of Proper Healthcare Infrastructure

Healthcare Expenditure
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Market

    • Biogen, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Pfizer Inc.
    • Glenmark Pharmaceuticals
    • Merck KGaA
    • Novartis AG
    • Sanofi-aventis Groupe
    • Teva Pharmaceutical Industries Ltd.
    • Boehringer Ingelheim International GmbH
    • Daiichi Sankyo Company, Limited
    • Siemens Healthcare GmbH


In The News

  • June, 2021: Novartis AG announced its collaboration with Hewlett Packard Enterprise to expand its distribution globally.
  • August, 2017: Sanofi-aventis and Bristol-Myers Squibb Company announced FDA approval for the antiplatelet agent PLAVIX.


Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Author Credits:  Radhika Gupta, Shivam Bhutani

Key Questions Answered in the Report

1) What are the major factors driving the growth of the candidiasis drugs market?

Ans: The increasing cases of candidiasis is estimated to boost the market growth.

2) What would be the CAGR of candidiasis drugs market over the forecast period?

Ans: The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 – 2030.

3) What are the challenges affecting the candidiasis drugs market growth?

Ans: Lack of health awareness amongst people is estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of candidiasis drugs market in future?

Ans: The market in the North America region is estimated to provide more business opportunities over the forecast period, owing to the higher prevalence of the disease in the region.

5) Who are the major players dominating the candidiasis drugs market?

Ans: The major players in the market are Pfizer Inc., Glenmark Pharmaceuticals, Merck KGaA, Novartis AG, Sanofi-aventis Groupe, Teva Pharmaceutical Industries Ltd., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the candidiasis drugs market?

Ans: The market is segmented by disease type, drug type, end-user, and by region.

8) Which segment captures the largest market size in end-user segment in the candidiasis drugs market?

Ans: The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy